Literature DB >> 17374739

Abnormal hematopoiesis in Gab2 mutant mice.

Yi Zhang1, Ernesto Diaz-Flores, Geqiang Li, Zhengqi Wang, Zizhen Kang, Eleonora Haviernikova, Sara Rowe, Cheng-Kui Qu, William Tse, Kevin M Shannon, Kevin D Bunting.   

Abstract

Gab2 is an important adapter molecule for cytokine signaling. Despite its major role in signaling by receptors associated with hematopoiesis, the role of Gab2 in hematopoiesis has not been addressed. We report that despite normal numbers of peripheral blood cells, bone marrow cells, and c-Kit(+)Lin(-)Sca-1(+) (KLS) cells, Gab2-deficient hematopoietic cells are deficient in cytokine responsiveness. Significant reductions in the number of colony-forming units in culture (CFU-C) in the presence of limiting cytokine concentrations were observed, and these defects could be completely corrected by retroviral complementation. In earlier hematopoiesis, Gab2-deficient KLS cells isolated in vitro responded poorly to hematopoietic growth factors, resulting in an up to 11-fold reduction in response to a cocktail of stem cell factor, flt3 ligand, and thrombopoietin. Gab2-deficient c-Kit(+)Lin(-) cells also demonstrate impaired activation of extracellular signal-regulated kinase (ERK) and S6 in response to IL-3, which supports defects in activating the phosphatidylinositol-3 kinase (PI-3K) and mitogen-associated protein kinase (MAPK) signaling cascades. Associated with the early defects in cytokine response, competitive transplantation of Gab2(-/-) bone marrow cells resulted in defective long-term multilineage repopulation. Therefore, we demonstrate that Gab2 adapter function is intrinsically required for hematopoietic cell response to early-acting cytokines, resulting in defective hematopoiesis in Gab2-deficient mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17374739      PMCID: PMC1896106          DOI: 10.1182/blood-2006-11-060707

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.

Authors:  M Golam Mohi; Ifor R Williams; Charles R Dearolf; Gordon Chan; Jeffery L Kutok; Sarah Cohen; Kelly Morgan; Christina Boulton; Hirokazu Shigematsu; Heike Keilhack; Koichi Akashi; D Gary Gilliland; Benjamin G Neel
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

2.  Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase.

Authors:  M Takahashi-Tezuka; Y Yoshida; T Fukada; T Ohtani; Y Yamanaka; K Nishida; K Nakajima; M Hibi; T Hirano
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

3.  Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation.

Authors:  H Gu; J C Pratt; S J Burakoff; B G Neel
Journal:  Mol Cell       Date:  1998-12       Impact factor: 17.970

4.  Identification of clonogenic common lymphoid progenitors in mouse bone marrow.

Authors:  M Kondo; I L Weissman; K Akashi
Journal:  Cell       Date:  1997-11-28       Impact factor: 41.582

5.  Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase.

Authors:  L Bi; I Okabe; D J Bernard; A Wynshaw-Boris; R L Nussbaum
Journal:  J Biol Chem       Date:  1999-04-16       Impact factor: 5.157

6.  Gab-family adapter proteins act downstream of cytokine and growth factor receptors and T- and B-cell antigen receptors.

Authors:  K Nishida; Y Yoshida; M Itoh; T Fukada; T Ohtani; T Shirogane; T Atsumi; M Takahashi-Tezuka; K Ishihara; M Hibi; T Hirano
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

7.  Phosphorylation of Grb2-associated binder 2 on serine 623 by ERK MAPK regulates its association with the phosphatase SHP-2 and decreases STAT5 activation.

Authors:  Mary Arnaud; Catherine Crouin; Catherine Deon; Denis Loyaux; Jacques Bertoglio
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

8.  Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.

Authors:  Toshiyuki Araki; M Golam Mohi; Fraz A Ismat; Roderick T Bronson; Ifor R Williams; Jeffery L Kutok; Wentian Yang; Lily I Pao; D Gary Gilliland; Jonathan A Epstein; Benjamin G Neel
Journal:  Nat Med       Date:  2004-07-25       Impact factor: 53.440

9.  Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.

Authors:  Mignon L Loh; Shashaank Vattikuti; Suzanne Schubbert; Melissa G Reynolds; Elaine Carlson; Kenneth H Lieuw; Jennifer W Cheng; Connie M Lee; David Stokoe; Jeannette M Bonifas; Nicole P Curtiss; Jason Gotlib; Soheil Meshinchi; Michelle M Le Beau; Peter D Emanuel; Kevin M Shannon
Journal:  Blood       Date:  2003-11-26       Impact factor: 22.113

10.  Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Authors:  Doan T Le; Namie Kong; Yuan Zhu; Jennifer O Lauchle; Abigail Aiyigari; Benjamin S Braun; Endi Wang; Scott C Kogan; Michelle M Le Beau; Luis Parada; Kevin M Shannon
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more
  25 in total

1.  A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.

Authors:  Sheng Zhou; Disha Mody; Suk See DeRavin; Julia Hauer; Taihe Lu; Zhijun Ma; Salima Hacein-Bey Abina; John T Gray; Michael R Greene; Marina Cavazzana-Calvo; Harry L Malech; Brian P Sorrentino
Journal:  Blood       Date:  2010-05-10       Impact factor: 22.113

2.  Gab2 promotes colony-stimulating factor 1-regulated macrophage expansion via alternate effectors at different stages of development.

Authors:  Angel W Lee; Yingwei Mao; Josef M Penninger; Soojie Yu
Journal:  Mol Cell Biol       Date:  2011-09-19       Impact factor: 4.272

3.  Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.

Authors:  Nicholas A Pullen; Brian O Barnstein; Yves T Falanga; Zhengqi Wang; Ryo Suzuki; Tenchee D Lama Tamang; Michele C Khurana; Emily A Harry; Petr Draber; Kevin D Bunting; Kazuya Mizuno; Bridget S Wilson; John J Ryan
Journal:  J Biol Chem       Date:  2011-11-30       Impact factor: 5.157

4.  Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells.

Authors:  Angelina Felici; Alessio Giubellino; Donald P Bottaro
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

Review 5.  GAB2--a scaffolding protein in cancer.

Authors:  Sarah J Adams; Iraz T Aydin; Julide T Celebi
Journal:  Mol Cancer Res       Date:  2012-08-07       Impact factor: 5.852

6.  Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein.

Authors:  Tilman Brummer; Mark Larance; Maria Teresa Herrera Abreu; Ruth J Lyons; Paul Timpson; Christoph H Emmerich; Emmy D G Fleuren; Gillian M Lehrbach; Daniel Schramek; Michael Guilhaus; David E James; Roger J Daly
Journal:  EMBO J       Date:  2008-09-03       Impact factor: 11.598

7.  Function, regulation and pathological roles of the Gab/DOS docking proteins.

Authors:  Franziska U Wöhrle; Roger J Daly; Tilman Brummer
Journal:  Cell Commun Signal       Date:  2009-09-08       Impact factor: 5.712

8.  Gab2 promotes hematopoietic stem cell maintenance and self-renewal synergistically with STAT5.

Authors:  Geqiang Li; Zhengqi Wang; Kristy L Miskimen; Yi Zhang; William Tse; Kevin D Bunting
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

9.  Interleukin-3 (IL-3)-induced c-fos activation is modulated by Gab2-calcineurin interaction.

Authors:  Saiju Pyarajan; Gabriel Matejovic; Joanne C Pratt; Shairaz Baksh; Steven J Burakoff
Journal:  J Biol Chem       Date:  2008-06-27       Impact factor: 5.157

10.  Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.

Authors:  Shengqing Gu; Wayne W Chan; Golam Mohi; Joel Rosenbaum; Azin Sayad; Zhibin Lu; Carl Virtanen; Shaoguang Li; Benjamin G Neel; Richard A Van Etten
Journal:  Blood       Date:  2016-01-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.